Novo Nordisk’s China Patent Pause and Washington Pivot Create a Split-Screen Reality

Novo Nordisk closed the week with a bang, its shares surging 6.7% to €35.16 on Friday. But beneath that single-day rally lies a far more complicated picture — one where a stroke of luck in China and early pill adoption are competing with a brutal Washington pricing battle and a stock still trading roughly 36% below where it stood a year ago.

A Fortuitous Delay in the World’s Second-Largest Drug Market

More than a month after Novo Nordisk’s semaglutide patent expired in China, not a single generic competitor has received approval to enter the market. That unexpected gap has handed the Danish drugmaker an unplanned extension of exclusivity in a country that generated roughly $1 billion in semaglutide sales last year across its Wegovy, Ozempic and Rybelsus franchises. The reprieve is particularly valuable given that patents in the U.S., Japan and Europe don’t expire until 2031 or 2032, making China the immediate battleground for generic encroachment.

Oral Wegovy Leaves Eli Lilly in the Dust — For Now

The competitive landscape for oral obesity treatments delivered another encouraging data point. In its first full week on the market, Eli Lilly’s newly launched pill Foundayo generated around 3,700 prescriptions. By contrast, Novo Nordisk’s oral Wegovy — which hit the U.S. market in January — racked up nearly 18,400 prescriptions in its second week. That’s a five-to-one advantage, though analysts caution that early prescribing patterns don’t always translate into durable market share.

The CagriSema pipeline, however, delivered a more sobering readout. The Phase 3 REDEFINE 4 study showed a 23% weight reduction but failed to meet its primary endpoint of non-inferiority versus Eli Lilly’s tirzepatide. Novo Nordisk is now planning higher-dose studies, with a Phase 3 start penciled in for the second half of 2026.

A Teenage Breakthrough Opens a New Front

The company also notched a clinical win that could open an entirely new patient demographic. The PIONEER TEENS trial demonstrated that oral semaglutide significantly reduced HbA1c levels compared with placebo in children and adolescents aged 10 to 17 with Type 2 diabetes, with a manageable safety profile. Regulatory filings in the U.S. and Europe are expected in the second half of 2026, potentially positioning Novo Nordisk as the first company to offer an oral GLP-1 agonist for this age group.

The Washington Chess Game Gets a New Player

Behind the clinical headlines, Novo Nordisk has quietly overhauled its political strategy in Washington — and the timing is no accident. On February 1, 2026, the company parted ways with Public Strategies Washington, a Democratic-leaning lobbying firm that had spent three and a half years pushing for better Medicare and Medicaid reimbursement for obesity drugs.

Should investors sell immediately? Or is it worth buying Novo Nordisk?

The move is not a retreat. Novo Nordisk still spends more than $8 million annually on lobbying, and its in-house team alone reported nearly $1.3 million in first-quarter 2026 expenditures. What has changed is the political alignment: out goes the Democratic-connected shop, in come firms with stronger Republican ties, including S-3 Group LLC, Nickles Group and Ballard Partners.

The reason for the pivot is concrete. The U.S. government has selected semaglutide — the active ingredient in both Ozempic and Wegovy — for Medicare price negotiation under the Inflation Reduction Act. Starting in 2027, Ozempic will be capped at $274 per month, down from a list price of $959. Higher doses of Wegovy will carry a Medicare price of $385 monthly. Novo Nordisk has sued to block the policy, so far without success. The D.C. Circuit Court of Appeals rejected challenges from multiple drugmakers, including Novo. However, the U.S. Chamber of Commerce has filed an amicus brief with the Supreme Court seeking review, keeping the legal avenue open even if a near-term ruling appears unlikely.

The Numbers That Matter

The options market has taken notice of the converging news flow. The put/call ratio on Novo Nordisk shares dropped to 0.29, far below its typical reading of around 0.75, signaling that traders are positioning for further upside. The stock’s relative strength index of roughly 18 also points to technically oversold conditions, which helps explain the recent bounce.

But the broader picture remains sobering. The shares are still down about 21% year-to-date and roughly 50% below their 52-week high of €70.13. Management has already guided for a 5% to 13% decline in both adjusted revenue and profit for 2026, driven by U.S. pricing pressure and patent expirations in select markets. CEO Mike Doustdar has called 2026 a “year of pricing pressure” and plans to offset the hit with volume gains and acquisitions.

The next major checkpoint arrives on May 6, when Novo Nordisk reports first-quarter results before the market opens. Analysts are looking for revenue of roughly $11.1 billion. The print will show whether the volume story is real enough to offset the pricing squeeze — and whether the stock’s recent rally has any fundamental fuel left behind it.